TY - JOUR
T1 - High level of IgG4 as a biomarker for a new subset of inflammatory bowel disease
AU - Wang, Zhujun
AU - Zhu, Min
AU - Luo, Chengxin
AU - Zhen, Yu
AU - Mu, Jingxi
AU - Zhang, Wenyan
AU - Ouyang, Qin
AU - Zhang, Hu
N1 - Funding Information:
This work was supported by National Natural Science Foundation of China [Grant Number: 81570502] and by Research Fund for the Doctoral Program of Higher Education of China (RFDP) [Grant Number: 20130181120041]. The authors are grateful to Prof. Yan Zhang, Prof. Renwei Hu, Prof. Yufang Wang and Dr. Zhonghui Wen for taking care of the patients.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - The roles of B and plasma cells in the pathogenesis of inflammatory bowel disease (IBD) are largely unrevealed. Data on the characteristics of IgG4 in patients with IBD are scarce. In this case-control study, serum IgG4 levels were comparable between patients with IBD and healthy individuals, whereas patients with IBD had dramatically higher mucosal IgG4 counts than healthy individuals. In patients with UC, mucosal IgG4 counts were positively correlated with serum IgG4 levels, serum IgG4/IgG ratios, and the Mayo Index; serum IgG4 levels and IgG4/IgG ratios were associated with a history of intestinal surgery and medications. A significant mucosal IgG4 count was found in 33.3% of patients with IBD, whereas, elevated serum IgG4 levels were found in only 9.9% of patients with IBD. Lesions were more severe and extensive in IBD patients with high levels of serum and mucosal IgG4. High levels of serum and mucosal IgG4 decreased after treatment with glucocorticoids or other immunosuppressants. High IgG4 level may be a biomarker for a new subset of IBD. More studies are warranted to explore this new subset of IBD for personalized therapy in the future.
AB - The roles of B and plasma cells in the pathogenesis of inflammatory bowel disease (IBD) are largely unrevealed. Data on the characteristics of IgG4 in patients with IBD are scarce. In this case-control study, serum IgG4 levels were comparable between patients with IBD and healthy individuals, whereas patients with IBD had dramatically higher mucosal IgG4 counts than healthy individuals. In patients with UC, mucosal IgG4 counts were positively correlated with serum IgG4 levels, serum IgG4/IgG ratios, and the Mayo Index; serum IgG4 levels and IgG4/IgG ratios were associated with a history of intestinal surgery and medications. A significant mucosal IgG4 count was found in 33.3% of patients with IBD, whereas, elevated serum IgG4 levels were found in only 9.9% of patients with IBD. Lesions were more severe and extensive in IBD patients with high levels of serum and mucosal IgG4. High levels of serum and mucosal IgG4 decreased after treatment with glucocorticoids or other immunosuppressants. High IgG4 level may be a biomarker for a new subset of IBD. More studies are warranted to explore this new subset of IBD for personalized therapy in the future.
UR - http://www.scopus.com/inward/record.url?scp=85049535912&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049535912&partnerID=8YFLogxK
U2 - 10.1038/s41598-018-28397-8
DO - 10.1038/s41598-018-28397-8
M3 - Article
C2 - 29968792
AN - SCOPUS:85049535912
SN - 2045-2322
VL - 8
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 10018
ER -